Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of SM03 plus methotrexate in moderate to severe active rheumatoid arthritis
CTR20170914Phase 3Completed
- Sponsor
- Longrui Pharmaceutical
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of suciraslimab in rheumatoid arthritis (RA), sponsored by Longrui Pharmaceutical. Started Jan 2018; status: completed.
02
Drugs
suciraslimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20170914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170914.